Current Pharmacogenomics and Personalized Medicine
Title:Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine)
Volume: 10 Issue: 1
Author(s): Vural Ozdemir, Erik Fisher, Edward S. Dove, Hilary Burton, Galen E. B. Wright, Mario Masellis and Louise Warnich
Affiliation:
Keywords: Africa, global personalized medicine, knowledge in mode 2, omics biotechnologies, P5 medicine, public health pharmacogenomics, science studies, sociomateriality
Export Options
About this article
Cite this article as:
Ozdemir Vural, Fisher Erik, S. Dove Edward, Burton Hilary, E. B. Wright Galen, Masellis Mario and Warnich Louise, Editorial (End of the Beginning and Public Health Pharmacogenomics: Knowledge in ‘Mode 2’ and P5 Medicine), Current Pharmacogenomics and Personalized Medicine 2012; 10 (1) . https://dx.doi.org/10.2174/1875692111201010001
DOI https://dx.doi.org/10.2174/1875692111201010001 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Advances in the Treatment of Triple-negative Early Breast Cancer
Medicinal Chemistry ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Editorial
Current Molecular Imaging (Discontinued) Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Cancer-related Fatigue, Inflammation and Thyrotropin-releasing Hormone
Current Aging Science Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets The Activity of Titanocene T Against Xenografted Caki-1 Tumors
Letters in Drug Design & Discovery At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine A Survey on Machine Learning Based Medical Assistive Systems in Current Oncological Sciences
Current Medical Imaging Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Ketogenic Diet Acts on Body Remodeling and MicroRNAs Expression Profile
MicroRNA Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy